Form 4: Halozyme Director Sells Shares Under 10b5-1 Plan

Halozyme Therapeutics Director Bernadette Connaughton sold 829 shares of common stock for $71.60 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Bernadette Connaughton, a Director of Halozyme Therapeutics, Inc. (HALO), reported a sale of common stock.
• The transaction involved the disposition of 829 shares of common stock.
• The shares were sold at a price of $71.60 per share, totaling $59,380.40.
• Following this transaction, the reporting person beneficially owns 42,123 shares of common stock directly.
• The sale was executed on December 1, 2025.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2025.

Sentiment

Score: 5

Explanation: Neutral. A routine insider sale under a pre-arranged 10b5-1 plan, which is common for corporate executives and directors for personal financial planning and diversification, and does not necessarily reflect a change in outlook on the company's prospects.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Minor impact on shareholders as it is a relatively small transaction for a director, executed under a pre-planned 10b5-1 arrangement, which reduces the implication of market timing.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale by a director under a pre-established 10b5-1 trading plan. Such sales are typically for personal financial planning and diversification and do not inherently signal a change in the company's fundamentals or future prospects. Therefore, this specific transaction alone does not warrant a change in investment recommendation, maintaining a 'hold' position based on broader company performance and market conditions.

Keywords

Halozyme Therapeutics, HALO, Insider Trading, Form 4, Stock Sale, Director, Bernadette Connaughton, 10b5-1 Plan, Equity Transaction